CMG Pharmaceutical Statistics

Total Valuation

CMG Pharmaceutical has a market cap or net worth of KRW 244.59 billion. The enterprise value is 238.40 billion.

Market Cap	244.59B
Enterprise Value	238.40B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

CMG Pharmaceutical has 138.89 million shares outstanding. The number of shares has decreased by -1.36% in one year.

Current Share Class	n/a
Shares Outstanding	138.89M
Shares Change (YoY)	-1.36%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	3.66%
Float	103.00M

Valuation Ratios

The trailing PE ratio is 164.20.

PE Ratio	164.20
Forward PE	n/a
PS Ratio	2.59
PB Ratio	1.25
P/TBV Ratio	1.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 28.32, with an EV/FCF ratio of -10.46.

EV / Earnings	82.36
EV / Sales	2.53
EV / EBITDA	28.32
EV / EBIT	45.68
EV / FCF	-10.46

Financial Position

The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.39.

Current Ratio	1.60
Quick Ratio	1.33
Debt / Equity	0.39
Debt / EBITDA	28.00
Debt / FCF	-3.36
Interest Coverage	-0.35

Financial Efficiency

Return on equity (ROE) is 1.49% and return on invested capital (ROIC) is -0.12%.

Return on Equity (ROE)	1.49%
Return on Assets (ROA)	-0.11%
Return on Capital (ROIC)	-0.12%
Revenue Per Employee	345.66M
Profits Per Employee	10.60M
Employee Count	273
Asset Turnover	0.34
Inventory Turnover	2.71

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -26.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-26.16%
50-Day Moving Average	1,982.66
200-Day Moving Average	2,135.79
Relative Strength Index (RSI)	38.94
Average Volume (20 Days)	469,778

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CMG Pharmaceutical had revenue of KRW 94.36 billion and earned 2.89 billion in profits. Earnings per share was 10.72.

Revenue	94.36B
Gross Profit	41.29B
Operating Income	-463.54M
Pretax Income	3.88B
Net Income	2.89B
EBITDA	2.74B
EBIT	-463.54M
Earnings Per Share (EPS)	10.72

Full Income Statement

Balance Sheet

The company has 82.84 billion in cash and 76.65 billion in debt, giving a net cash position of 6.19 billion or 44.57 per share.

Cash & Cash Equivalents	82.84B
Total Debt	76.65B
Net Cash	6.19B
Net Cash Per Share	44.57
Equity (Book Value)	196.03B
Book Value Per Share	1,411.38
Working Capital	49.93B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.87 billion and capital expenditures -30.65 billion, giving a free cash flow of -22.78 billion.

Operating Cash Flow	7.87B
Capital Expenditures	-30.65B
Free Cash Flow	-22.78B
FCF Per Share	-164.03

Full Cash Flow Statement

Margins

Gross margin is 43.76%, with operating and profit margins of -0.49% and 3.07%.

Gross Margin	43.76%
Operating Margin	-0.49%
Pretax Margin	4.11%
Profit Margin	3.07%
EBITDA Margin	2.90%
EBIT Margin	-0.49%
FCF Margin	n/a

Dividends & Yields

CMG Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.36%
Shareholder Yield	1.36%
Earnings Yield	0.61%
FCF Yield	-9.31%

Stock Splits

The last stock split was on August 28, 2007. It was a forward split with a ratio of 2.

Last Split Date	Aug 28, 2007
Split Type	Forward
Split Ratio	2

Scores

CMG Pharmaceutical has an Altman Z-Score of 2.28. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.28
Piotroski F-Score	n/a